Dylan Dupuis
Stock Analyst at Roth MKM
(2.65)
# 1,951
Out of 4,789 analysts
9
Total ratings
44.44%
Success rate
33.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $7 | $1.09 | +542.20% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $2.94 | +274.15% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $2.76 | +733.33% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $24.15 | +32.51% | 1 | May 31, 2023 | |
| UBX Unity Biotechnology | Initiates: Buy | $10 | $1.04 | +861.54% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $7
Current: $1.09
Upside: +542.20%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $2.94
Upside: +274.15%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $2.76
Upside: +733.33%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $24.15
Upside: +32.51%
Unity Biotechnology
May 31, 2023
Initiates: Buy
Price Target: $10
Current: $1.04
Upside: +861.54%